A U.S. federal judge rejected Swiss drugmaker Novartis' request for a preliminary injunction to stop MSN Pharmaceuticals from ...

Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug ...

A federal judge has denied Novartis (SIX:NOVN)’ request for a preliminary injunction that would have prevented MSN Pharmaceuticals from selling a generic version of heart medication Entresto.

A federal judge in New Jersey denied a preliminary injunction sought by Novartis (NYSE:NVS) to block MSN Pharmaceuticals from launching a generic version of the former’s blockbuster heart failure ...

A Delaware federal judge has ruled that Novartis cannot prevent MSN Pharmaceuticals from introducing a generic version of its ...

The shares of one of India's leading API manufacturers, engaged in the production and export of APIs, intermediates, and ...

The company's quarterly core operating profit--the company's preferred earnings metric, which strips out exceptional and other one-off items--is forecast at $5.75 billion, according to the same ...

Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.

Strong sales of Entresto, Kisqali, Kesimpta, Leqvio and Scemblix have likely benefited NVS' Q2 performance and offset the ...

Brokerage firm IIFL has warned that due to this development, Divi's Laboratories' annual Earnings Before Interest, Tax, ...

Medicare Advantage plans with drug coverage will also cover Entresto. Out-of-pocket costs may vary depending on factors such as the individual’s dosage and pharmacy pricing.